These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 2475458)
21. [Determination of prostatic specific antigen and prostatic acid phosphatase as tumor markers of cancer of the prostate]. Morote Robles J; de Torres Mateos JA Arch Esp Urol; 1989; 42 Suppl 2():124-30. PubMed ID: 2484148 [TBL] [Abstract][Full Text] [Related]
22. Advanced prostate cancer follow-up with prostate-specific antigen, prostatic acid phosphatase, osteocalcin and bone isoenzyme of alkaline phosphatase. Curatolo C; Ludovico GM; Correale M; Pagliarulo A; Abbate I; Cirrillo Marucco E; Barletta A Eur Urol; 1992; 21 Suppl 1():105-7. PubMed ID: 1385127 [TBL] [Abstract][Full Text] [Related]
23. Occult carcinoma of the prostate. El-Morsi AR J Egypt Med Assoc; 1974; 57(7-8):373-7. PubMed ID: 4452775 [No Abstract] [Full Text] [Related]
24. Immunologic markers and the diagnosis of prostatic cancer. Ban Y; Wang MC; Chu TM Urol Clin North Am; 1984 May; 11(2):269-76. PubMed ID: 6203206 [TBL] [Abstract][Full Text] [Related]
25. Multiple marker evaluation in human prostate cancer with the use of tissue-specific antigens. Kuriyama M; Wang MC; Lee CL; Killian CS; Papsidero LD; Inaji H; Loor RM; Lin MF; Nishiura T; Slack NH; Murphy GP; Chu TM J Natl Cancer Inst; 1982 Jan; 68(1):99-105. PubMed ID: 6172628 [TBL] [Abstract][Full Text] [Related]
26. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM). Roobol MJ; Kranse R; de Koning HJ; Schröder FH Urology; 2004 Feb; 63(2):309-13; discussion 313-5. PubMed ID: 14972478 [TBL] [Abstract][Full Text] [Related]
27. [The role of prostate specific antigen in diagnosis of localized adenocarcinoma of the prostate. Nara Uro-Oncology Research Group]. Hirao Y; Ozono S; Kagebayashi Y; Yoshi M; Tani Y; Uemura H; Momose H; Okajima E Hinyokika Kiyo; 1996 Oct; 42(10):795-804. PubMed ID: 8951478 [TBL] [Abstract][Full Text] [Related]
28. Prostate-specific antigen in adenocarcinoma of the prostate. N Engl J Med; 1988 Apr; 318(15):992-3. PubMed ID: 2451131 [No Abstract] [Full Text] [Related]
29. Benign positive margins after radical prostatectomy means a poor prognosis--pro. Djavan B; Milani S; Fong YK Urology; 2005 Feb; 65(2):218-20. PubMed ID: 15708025 [No Abstract] [Full Text] [Related]
30. The value of prostatic acid phosphatase and prostate specific antigen as serum markers in carcinoma of the prostate. Akdaş A; Simşek F; Ilker Y; Türkeri L; Ercan H Int Urol Nephrol; 1993; 25(3):271-8. PubMed ID: 7693607 [TBL] [Abstract][Full Text] [Related]
31. [Role of prostate-specific antigen in prostatic carcinoma. Validity of an integrated methodologic approach and morpho-biological correlations]. Tomasino RM; Lo Bianco A; Cacciatore M; Pavone C; Carreca I; Morello V; Salvato M; Florena AM; Pavone-Macaluso M Pathologica; 1989; 81(1072):109-26. PubMed ID: 2475847 [TBL] [Abstract][Full Text] [Related]
32. Benign positive margins after radical prostatectomy means a poor prognosis--con. Rubin MA; Montie JE Urology; 2005 Feb; 65(2):221-3. PubMed ID: 15708026 [No Abstract] [Full Text] [Related]
33. [The value of prostate-specific antigen]. Wirth M Urologe A; 1991 May; 30(3 Suppl):6. PubMed ID: 1720907 [No Abstract] [Full Text] [Related]
34. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer. Noguchi M; Noda S J Urol; 2001 Sep; 166(3):1106-10. PubMed ID: 11490307 [TBL] [Abstract][Full Text] [Related]